Management of Grade 2 Gastroparesis

Prokinetic Therapy

The American Gastroenterological Association recommends domperidone 10 mg three times daily as the preferred alternative prokinetic agent for Grade 2 gastroparesis when metoclopramide is contraindicated, due to its prokinetic effects with significantly fewer CNS side effects 1, 2
Domperidone should not exceed 10 mg three times daily due to the risk of QT prolongation and ventricular tachycardia, with a recommended baseline ECG to assess QTc interval and correct electrolyte abnormalities before initiating therapy 1, 2, 4
Clinical studies show 68% of gastroparesis patients had symptom improvement with domperidone, though 7% required cessation due to cardiac side effects 2

The American Gastroenterological Association recommends 5-HT3 receptor antagonists, such as ondansetron 4-8 mg twice or three times daily or granisetron 1 mg twice daily, as equally effective options for nausea control in Grade 2 gastroparesis 1, 2, 3
Granisetron transdermal patch 34.3 mg weekly offers convenient dosing and has demonstrated a 50% reduction in symptom scores in refractory gastroparesis 1, 2
Aprepitant 80 mg daily may benefit up to one-third of patients with troublesome nausea, although cost may be prohibitive for many patients 1, 2, 3

The American Gastroenterological Association recommends nortriptyline or desipramine 25-100 mg daily as preferred tricyclic antidepressants for visceral pain management in Grade 2 gastroparesis 1, 2, 3
Gabapentin >1200 mg daily in divided doses or pregabalin 100-300 mg daily can be used for neuropathic-type pain 1, 2, 3

Baseline ECG and periodic monitoring of QTc interval are recommended for patients on domperidone, as well as checking electrolytes before initiation 4
Nutritional assessment, including monitoring weight, vitamin B12, vitamin D, iron, and calcium levels, is essential for all patients with Grade 2 gastroparesis 3